Biomarker Panel Predicts Cardiac Regeneration Response
Solution Overview
Problem
Current regenerative therapies for heart tissue, particularly those involving bone marrow stem cells, face challenges in predicting response to cardiovascular regeneration due to the lack of understanding of regenerative mechanisms and the role of CD34+ Endothelial Progenitor Cells, leading to inconsistent clinical outcomes.
Innovation Solution
A method for predicting response to cardiovascular regeneration by determining specific biomarkers such as Growth factor, Lymphocyte adapter protein, Glycoprotein, brain natriuretic peptide, circulating endothelial progenitor cells, circulating endothelial cells, circulating thrombocytes, and receptor/ligand expression on mononuclear cells, which involves measuring their amounts in a sample and comparing them to baseline values to assess the likelihood of cardiac regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone marrow stem cell therapy is applied for cardiovascular regeneration, then therapeutic intervention is provided, but prediction accuracy of treatment response remains low
Solution Approach 1:
The patent applies preliminary action by measuring biomarker levels (CD34+ EPCs, CD133+ EPCs, soluble CD133, VEGF, EPO) before stem cell therapy to predict treatment response. This pre-assessment allows identification of patients likely to benefit from therapy, enabling informed treatment decisions before the actual therapeutic intervention occurs.
Solution Approach 2:
The patent implements feedback by using biomarker measurements to provide information about the likelihood of treatment response. This feedback mechanism allows clinicians to adjust treatment decisions based on predicted response, creating a closed-loop system where treatment selection is informed by predictive biological markers rather than empirical trial-and-error.
2Reliability
If multiple biomarkers are measured to improve prediction accuracy, then prediction reliability increases, but device complexity and measurement requirements increase
Solution Approach 1:
The patent applies universality by using a panel of biomarkers that serve multiple predictive functions simultaneously. The same set of biomarkers (CD34+ EPCs, CD133+ EPCs, soluble CD133, VEGF, EPO) provides comprehensive information about different aspects of regenerative potential, allowing a single measurement system to perform multiple assessment functions.
Solution Approach 2:
The patent merges multiple individual biomarker measurements into a composite predictive assessment. By combining information from five different biomarkers, the system creates a more robust prediction than any single marker could provide alone, while the merged approach streamlines the overall assessment process.
Data Source
AI summary
The present invention relates to a method for prediction of response to cardiovascular regeneration comprising the use of biomarkers. Further, the present invention relates to a combination of the biomarkers for use in a method for prediction of response to cardiovascular regeneration, a computer device to perform a method according to the present invention and a device adapted for carrying out the inventive method.